Primary Mediastinal Large B-Cell Lymphoma

Observed

→ investigated in trials for

Fludarabinesmall molecule

18 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rituximabmonoclonal antibody

14 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

10 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Epcoritamabmonoclonal antibody

9 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Axicabtagene Ciloleucelgene_therapy

7 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lisocabtagene Maraleucelgene therapy

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Primary Mediastinal Large B-Cell Lymphoma studied in …STUDIED_INderived10 of 127show all (up to 200)
→ studied in	NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07168486Phase 1 · enrolling by invitation CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05934084NA · recruiting Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04759586Phase 3 · active not recruiting Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)	—	—	Primary Mediastinal Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →

Primary Mediastinal Large B-Cell Lymphoma studied in …STUDIED_INderived10 of 127show all (up to 200)

→ studied in

NCT06784167recruiting

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT05359211Phase 1 · completed

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT04231877Phase 1 · active not recruiting

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT05025800Phase 1/Phase 2 · active not recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT07168486Phase 1 · enrolling by invitation

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT05934084NA · recruiting

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT06830031Phase 1 · recruiting

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT07098364Phase 1/Phase 2 · suspended

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT04759586Phase 3 · active not recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed

→ studied in

NCT03625037Phase 1/Phase 2 · active not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 127 trials mapped (71 active)

—

Observed